[go: up one dir, main page]

MX2009006285A - Inhibidores de transcriptasa inversa no nucleosidicos. - Google Patents

Inhibidores de transcriptasa inversa no nucleosidicos.

Info

Publication number
MX2009006285A
MX2009006285A MX2009006285A MX2009006285A MX2009006285A MX 2009006285 A MX2009006285 A MX 2009006285A MX 2009006285 A MX2009006285 A MX 2009006285A MX 2009006285 A MX2009006285 A MX 2009006285A MX 2009006285 A MX2009006285 A MX 2009006285A
Authority
MX
Mexico
Prior art keywords
sup
reverse transcriptase
transcriptase inhibitors
compounds
nucleoside reverse
Prior art date
Application number
MX2009006285A
Other languages
English (en)
Inventor
Neville J Anthony
Robert Gomez
Samson M Jolly
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MX2009006285A publication Critical patent/MX2009006285A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Los compuestos de la Fórmula I: (ver fórmula (I)) son inhibidores de transcriptasa inversa de VIH, en la que Q, R2, R3, R6, T1, T2, y T3 se definene en el presente documento. Los compuestos de la Fórmula I, y sus sales y profármacos farmacéuticamente aceptables, son de utilidad en la inhibición de transcriptasa inversa de VIH, en la profilaxis y tratamiento de infección por VIH y en la profilaxis, retraso del inicio o de la progresión, y tratamiento del SIDA. Los compuestos y sus sales pueden emplearse como ingredientes en composiciones farmacéuticas, opcionalmente combinados con otros antivirales, inmunomoduladores, antibióticos o vacunas.
MX2009006285A 2006-12-13 2007-12-06 Inhibidores de transcriptasa inversa no nucleosidicos. MX2009006285A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87462906P 2006-12-13 2006-12-13
PCT/US2007/024974 WO2008076223A1 (en) 2006-12-13 2007-12-06 Non-nucleoside reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
MX2009006285A true MX2009006285A (es) 2009-06-23

Family

ID=39277099

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006285A MX2009006285A (es) 2006-12-13 2007-12-06 Inhibidores de transcriptasa inversa no nucleosidicos.

Country Status (29)

Country Link
US (2) US7781454B2 (es)
EP (1) EP2121638B1 (es)
JP (1) JP5123949B2 (es)
KR (1) KR20090087481A (es)
CN (1) CN101558050A (es)
AR (1) AR064199A1 (es)
AU (1) AU2007334598B2 (es)
BR (1) BRPI0720196A2 (es)
CA (1) CA2673093A1 (es)
CL (1) CL2007003594A1 (es)
CR (1) CR10843A (es)
DO (1) DOP2009000138A (es)
EA (1) EA200970572A1 (es)
EC (1) ECSP099373A (es)
GE (1) GEP20115320B (es)
GT (1) GT200900158A (es)
HN (1) HN2009001160A (es)
IL (1) IL199103A0 (es)
MA (1) MA31036B1 (es)
MX (1) MX2009006285A (es)
NI (1) NI200900103A (es)
NO (1) NO20092636L (es)
NZ (1) NZ577637A (es)
PE (1) PE20081448A1 (es)
SV (1) SV2009003294A (es)
TN (1) TN2009000243A1 (es)
TW (1) TW200831085A (es)
WO (2) WO2008076225A2 (es)
ZA (1) ZA200903395B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TWI475995B (zh) 2007-09-14 2015-03-11 Janssen Pharmaceuticals Inc １’，３’－二取代－４－苯基－３，４，５，６－四氫－２ｈ，１’ｈ－〔１，４’〕聯吡啶基－２’－酮化物
JP5433579B2 (ja) 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換−４−フェニル−１ｈ−ピリジン−２−オン
ATE516272T1 (de) 2007-09-14 2011-07-15 Ortho Mcneil Janssen Pharm 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
AU2008323287B2 (en) 2007-11-14 2011-07-14 Addex Pharma S.A. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2220084B1 (en) * 2007-11-16 2014-02-19 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
RU2010125220A (ru) * 2007-11-20 2011-12-27 Мерк Шарп Энд Домэ Корп. (Us) Ненуклеозидные ингибиторы обратной транскриптазы
WO2009117278A2 (en) * 2008-03-20 2009-09-24 Merck & Co., Inc. Processes for preparing (amino-pyrazolopyridinyl)methoxy substituted biaryl ethers
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
WO2011049987A2 (en) * 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
DK2924034T3 (en) 2010-03-30 2017-02-06 Merck Canada Inc PHARMACEUTICAL COMPOSITION CONTAINING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
WO2012078416A2 (en) * 2010-12-06 2012-06-14 Rfs Pharma, Llc Monophosphate prodrugs of dapd and analogs thereof
CN103732216A (zh) * 2011-08-16 2014-04-16 默沙东公司 无机基质和有机聚合物组合用于制备稳定的无定形分散体的用途
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
PL2861566T3 (pl) 2012-06-13 2017-06-30 F.Hoffmann-La Roche Ag Nowy diazaspirocykloalkan i azaspirocykloalkan
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CN103848826A (zh) * 2012-11-30 2014-06-11 南京大学 一类含苯并三氮唑结构的1,3,4-恶二唑类衍生物的制法与用途
CN103848827A (zh) * 2012-11-30 2014-06-11 南京大学 一种含苯并三氮唑类衍生物在抗癌药物中的应用
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
HUE036117T2 (hu) 2013-11-26 2018-06-28 Hoffmann La Roche Oktahidro-ciklobuta[1,2-C;3,4-C']dipirrol származékok, mint autotaxin inhibitorok
EP3424535A1 (en) 2014-01-21 2019-01-09 Janssen Pharmaceutica NV Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
PH12019500127B1 (en) 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
JP6554481B2 (ja) 2014-03-26 2019-07-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ オートタキシン（ａｔｘ）及びリゾホスファチジン酸（ｌｐａ）産生の阻害剤としての縮合［１，４］ジアゼピン化合物
EA037928B1 (ru) 2014-03-26 2021-06-08 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
CA2944187C (en) 2014-04-01 2018-06-19 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CR20180058A (es) 2015-09-04 2018-02-26 Hoffmann La Roche Nuevos derivados de fenoximetilo
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
CN107922412B (zh) 2015-09-24 2021-02-23 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
EP3353178B1 (en) 2015-09-24 2021-07-14 F. Hoffmann-La Roche AG Bicyclic compounds as dual atx/ca inhibitors
MX2017015034A (es) 2015-09-24 2018-04-13 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
CN105906482B (zh) * 2016-05-19 2019-02-12 江苏优嘉植物保护有限公司 一种利用2,5-二氯酚醚制备2,5-二氯苯酚的方法
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
AU2019402998B2 (en) 2018-12-18 2022-12-15 Merck Sharp & Dohme Llc Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells
EP3986477A1 (en) 2019-06-21 2022-04-27 Ascendis Pharma A/S CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS
US20230024438A1 (en) * 2019-12-04 2023-01-26 Arcus Biosciences, Inc. Inhibitors of hif-2alpha
CN114031619A (zh) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 一种图卡替尼中间体的制备方法
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036976A (en) * 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
SU1049487A1 (ru) * 1982-06-24 1983-10-23 Новокузнецкий научно-исследовательский химико-фармацевтический институт Способ получени @ -аминокетонов бензимидазольного р да
US5358950A (en) * 1991-07-05 1994-10-25 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists
US5527819A (en) * 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
US6369235B1 (en) * 1997-02-25 2002-04-09 The United States Of America As Represented By The Department Of Health And Human Services Substituted benzimidazoles, and methods of use thereof, for the inhibition of HIV reverse transcription and for the treatment of HIV infection
US6977262B2 (en) * 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
WO2004014364A1 (en) * 2002-08-07 2004-02-19 Idenix (Cayman) Limited Substituted phenylindoles for the treatment of hiv
ATE327977T1 (de) * 2002-10-21 2006-06-15 Warner Lambert Co Tetrahydrochinolin-derivate als crth2 antagonisten
US7365209B2 (en) * 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
AU2004218463B2 (en) * 2003-03-03 2009-07-16 Array Biopharma, Inc. p38 inhibitors and methods of use thereof
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
BRPI0508036A (pt) * 2004-02-27 2007-07-17 Hoffmann La Roche derivados fundidos de pirazola
BRPI0508220A (pt) * 2004-02-27 2007-07-17 Hoffmann La Roche derivados de pirazol heteroarila fundidos
US7625949B2 (en) * 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
US7166738B2 (en) * 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
WO2005115147A2 (en) * 2004-05-18 2005-12-08 Merck & Co., Inc. Hiv reverse transcriptase inhibitors
US7687638B2 (en) * 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP4675959B2 (ja) * 2004-07-27 2011-04-27 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としてのベンジルトリアゾロン化合物
JP2008537548A (ja) * 2005-03-24 2008-09-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ プロキネチシン１受容体
EP1898927A2 (en) 2005-06-28 2008-03-19 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
JP2008546839A (ja) 2005-06-28 2008-12-25 メルク エンド カムパニー インコーポレーテッド 非ヌクレオシド逆転写酵素阻害剤
WO2007002368A2 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
CN101501002B (zh) * 2006-08-16 2012-06-27 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
RU2456281C2 (ru) * 2006-11-16 2012-07-20 Ф. Хоффманн-Ля Рош Аг Замещенные 4-имидазолы, способ их получения и их применение
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
AR064199A1 (es) 2009-03-18
AU2007334598A1 (en) 2008-06-26
MA31036B1 (fr) 2009-12-01
GEP20115320B (en) 2011-10-25
ECSP099373A (es) 2009-07-31
BRPI0720196A2 (pt) 2013-12-31
JP5123949B2 (ja) 2013-01-23
HN2009001160A (es) 2011-10-11
CR10843A (es) 2009-08-12
AU2007334598B2 (en) 2013-01-17
WO2008076223A1 (en) 2008-06-26
IL199103A0 (en) 2010-03-28
CA2673093A1 (en) 2008-06-26
GT200900158A (es) 2009-10-14
TW200831085A (en) 2008-08-01
TN2009000243A1 (en) 2010-10-18
EA200970572A1 (ru) 2009-12-30
US20080275097A1 (en) 2008-11-06
CN101558050A (zh) 2009-10-14
US20100286192A1 (en) 2010-11-11
CL2007003594A1 (es) 2008-05-30
JP2010510989A (ja) 2010-04-08
EP2121638B1 (en) 2016-05-25
US7781454B2 (en) 2010-08-24
NZ577637A (en) 2011-05-27
WO2008076225A2 (en) 2008-06-26
NO20092636L (no) 2009-09-08
DOP2009000138A (es) 2009-11-15
KR20090087481A (ko) 2009-08-17
EP2121638A2 (en) 2009-11-25
ZA200903395B (en) 2010-05-26
SV2009003294A (es) 2009-11-09
NI200900103A (es) 2010-01-26
WO2008076225A3 (en) 2008-08-07
PE20081448A1 (es) 2008-10-19

Similar Documents

Publication Publication Date Title
MX2009006285A (es) Inhibidores de transcriptasa inversa no nucleosidicos.
WO2008054605A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2007146230A3 (en) Non-nucleoside reverse transcriptase inhibitors
MY163979A (en) Non-nucleoside reverse transcriptase inhibitors
WO2005086700A3 (en) Hiv integrase inhibitors
MD4625B1 (ro) Derivaţi de 5-fenoxi-3H-pirimidin-4-onă şi utilizarea acestora ca inhibitori ai transcriptazei inverse a HIV
WO2006103399A8 (en) Hiv integrase inhibitors
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
TW200738702A (en) HIV reverse transcriptase inhibitors
WO2010042391A3 (en) Hiv integrase inhibitors
EP1467970A4 (en) HYDROXYNAPHTHYRIDINONCARBOXYL ACID AMIDES SUFFICIENT AS INHIBITORS OF THE HIV INTEGRASE
EA200601654A1 (ru) Ингибиторы интегразы вич
WO2006121831A3 (en) Hiv integrase inhibitors
WO2009042094A3 (en) Hiv protease inhibitors
WO2011025683A8 (en) Hiv integrase inhibitors
WO2005110414A3 (en) Hiv integrase inhibitors
WO2007050510A3 (en) Hiv integrase inhibitors
ATE517899T1 (de) Hiv-integrasehemmer
EP1539714A4 (en) 8-HYDROXY-1-OXOTETRAHYDROPYRROLOPYRAZIN COMPOUNDS SUITABLE AS INHIBITORS OF HIV INTEGRASE
WO2007002458A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2007002481A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2007021629A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2007002368A3 (en) Non-nucleoside reverse transcriptase inhibitors
TN2011000151A1 (en) Hiv integrase inhibitors
TW200640460A (en) HIV integrase inhibitors

Legal Events

Date Code Title Description
HH Correction or change in general
HC Change of company name or juridical status
FG Grant or registration